SB297006 is primarily utilized in research settings as a selective antagonist for the CCR3 receptor. This receptor is involved in the recruitment of eosinophils, a type of white blood cell, to sites of inflammation. By inhibiting CCR3, SB297006 helps in studying the role of eosinophils in allergic reactions and inflammatory diseases such as asthma, eczema, and allergic rhinitis. Its application is crucial for understanding the underlying mechanisms of these conditions and for the development of potential therapeutic agents targeting eosinophil-mediated inflammation. Additionally, SB297006 is used in pharmacological studies to explore the broader implications of CCR3 inhibition in other inflammatory and immune-related disorders.